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Glucuronidation of iodothyronines in rat liver is cata- 
lyzed by at least three UDP-glucuronyltransferases 
(UGTs): bilirubin UGT, phenol UGT, and androster- 
one UGT. Bilirubin and phenol UGT activities are regu- 
lated by thyroid hormone, but the effect of thyroid 
status on hepatic glucuronidation of iodothyronines is 
unknown. We examined the effects of hypothyroidism 
induced by treatment of rats with propylthiouracil 
(PTU) or methimazole (MMI) or by thyroidectomy as 
well as the effects of T4-induced hyperthyroidism on 
the hepatic UGT activities for T4, T3, bilirubin, 
p-nitrophenol (PNP), and androsterone. Bilirubin UGT 
activity was increased in MMI- or PTU-induced hypo- 
thyroid and thyroidectomized rats, and decreased in 
hyperthyroid animals. T4 and, to a lesser extent, T3 
UGT activities were increased in MMI- or PTU-induced 
hypothyroid rats, and T4 but not T3 glucuronidation 
also showed a significant increase in thyroidectomized 
rats. T4 but not T3 UGT activity was slightly decreased 
in hyperthyroid rats. While PNP UGT activity was 
decreased in thyroidectomized rats and increased in 
hyperthyroid animals, it was also markedly increased 
by MMI and slightly increased by PTU-induced hypo- 
thyroidism. In T4-substituted rats, MMI did not affect 
T4, T3, bilirubin and androsterone UGT activities but 
again strongly induced PNP UGT activity, indicating 
that this represented a direct induction of PNP UGT by 
the drug independent of its thyrostatic action. Andros- 
terone UGT activity was hardly affected by thyroid 
status. Our results suggest a modest, negative control 
of the hepatic glucuronidation of thyroid hormone by 
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thyroid status, which may be mediated by changes in 
bilirubin UGT activity. To our knowledge, this is the 
first report of the marked induction of a hepatic enzyme 
by MMI, which is not mediated by its thyroid hormone- 
lowering effect. 
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Introduction 
Deiodination is the primary pathway of thyroid hormone 
metabolism, since it is involved with the regulation of hor- 
monal activity (K6hrle et al. 1991 ;St. Germain, 1994). The 
prohormone T4 is converted by outer ring deiodination 
(ORD) to bioactive T3 and by inner ing deiodination (IRD) 
to inactive rT3. IRD is also a major step in the inactivation 
ofT3, yielding the same metabolite (3,3'-diiodothyronine) 
as that generated by ORD of rT3 (K6hrle et al. 1991; St. 
Germain, 1994). 
Conjugation of the phenolic hydroxyl group with sulfate 
or glucuronic acid represents other important metabolic 
pathways for thyroid hormone (Visser, 1990, 1994; Curran 
and DeGroot, 1991). In general, conjugation is a detoxifi- 
cation reaction that increases the water-solubility ofendog- 
enous and foreign compounds, thus facilitating their 
excretion in bile and/or urine. However, sulfation of 
iodothyronines is an exceptional case, since it strongly 
accelerates the deiodination of these compounds by the 
type I iodothyronine deiodinase (ID-I). Therefore, under 
normal conditions, very little thyroid hormone sulfates are 
detected inblood, bile, or urine, but they accumulate o high 
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levels in situations where ID-I activity is inhibited (Visser, 
1990, 1994; Curran and DeGroot, 1991). 
Thyroid hormone is glucuronidated byUDP-glucuronyl- 
transferases (UGTs) located in the endoplasmic reticulum 
of liver and other tissues (Visser, 1990, 1994; Curran and 
DeGroot, 1991 ). Iodothyronine glucuronides are excreted in 
bile, but this is not an irreversible route for thyroid hormone 
disposal. The glucuronides are extensively deconjugated in 
the intestinal lumen, in particular by 13-glucuronidases of 
bacterial origin, and part of the liberated iodothyronines is 
reabsorbed (Hazenberg et al., 1988; De Herder et al., 1989; 
Rutgers et al., 1989). Because of this enterohepatic circu- 
lation, the intestinal content represents a large pool of thy- 
roid hormone (Nguyen et al., 1993). 
Previous studies in our laboratory have suggested that 
at least three UGT isoenzymes are involved with the 
glucuronidation of iodothyronines in rats (Beetstra et al., 
1991; Visser et al., 1991 a, 1993a, 1993b, 1993c; Van Raaij 
et al., 1993). Especially T4 and rT3 are glucuronidated by 
one of the bilirubin UGTs as well as by one of the phenol 
UGTs. However, T3 is predominantly glucuronidated by 
androsterone UGT (Visser et al., 1993b). Despite the quan- 
titative importance of the glucuronidation of thyroid hor- 
mone, at least in rats, little is known about its regulation. In 
this study, we addressed the question of whether the 
glucuronidation of thyroid hormone in rats is regulated by 
thyroid status. For this, we investigated the effects of 
hypothyroidism induced by the goitrogens 6-propyl-2- 
thiouracil (PTU) or methimazole (MMI) and those of 
hyperthyroidism induced by T4 treatment on the liver 
microsomal UGT activities for T4, T3, bilirubin, p-nitro- 
phenol (PNP), and androsterone. The efficacy of these treat- 
ments was checked by analysis of serum T4, T3, and TSH 
levels as well as hepatic ID-I activity, which is positively 
regulated by thyroid status (K/)hrle et al., 1991 ;St. Germain, 
1994). Among other things, the results demonstrate a 
potent induction of PNP UGT activity by MMI, which is 
not mediated by its thyroid hormone-lowering action. 
Results  
Table 1 shows the effects of treatment of rats for 2 wk 
with PTU or MMI on serum T4 and T3 levels as well as on 
hepatic ID-I activity. Both goitrogens produced an 80% 
decrease in serum T4 and a 60% decrease in serum T3. 
The hypothyroid status of the liver in MMI-treated rats 
was substantiated by the 70% decrease in ID-I activity. 
The greater decrease in ID-I activity induced by PTU is 
explained by the direct inhibition of ID-I by this drug. 
Figure 1 shows the effects of PTU or MMI treatment on 
hepatic UGT activities for different substrates. Both PTU 
and MMI induced significant increases in T4 and T3 UGT 
activities, the effects being greater with T4 than with T3 as 
substrate. Whereas PTU treatment resulted in a small 
increase in PNP UGT activity, a 130% increase in PNP 
Table 1 
Effects of Treatment of Rats with PTU or MMI 
on Serum T4 and T3 Levels and Hepatic [D-I Activity a 
Group 
Parameter Control PTU MMI 
T4, nmol/L 6 !+5 13_+2 b 13_+2 h
T3, nmol/L 1.31+0.11 0.51_+0.10 t' 0.47_+0.11 ~'
ID-I, pmol/min/mg 462 _+ 51 47 + 11 b 153 + 97/' 
Rat treatment was for 2 wk with 0.1% (wt/vol) PTU or M MI 
in the drinking water. Results are presented asmean +_ SD of eight 
rats in each group. 
hp < 0.001 vs control. 
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Fig. 1. Effects of treatment of rats for 2 wk with 0.1% (wt/vol) 
PTU or MMI in the drinking water on hepatic UGT activities. 
Results are expressed aspercentage of the mean control value (T4 
1.05 pmol, T3 0.75 pmol, PNP 51 nmol, bilirubin 0.62 nmol, and 
androsterone 2.68 nmo! per min and per mg protein), and pre- 
sented as mean + SD of eight rats per group. O, p < 0.025 vs 
control; O,p < 0.01 vs control; *, p < 0.001 vs control. 
UGT activity was observed in MMI-treated rats. Both PTU 
and MMI induced a ~100% increase in bilirubin UGT 
activity and a slight but significant increase in androsterone 
UGT activity. 
Table 2 shows that serum T4 and T3 levels in rats treated 
with substitution doses ofT4 in combination with MMI did 
not differ from those in rats treated with T4 alone. Table 2 
also demonstrates that hepatic deiodinase activity was not 
affected by MMI in "T4-substituted" rats. 
Figure 2 shows the effects of treatment of T4-substituted 
rats with MMI on hepatic UGT activities. The results clearly 
show that T4 and T3 UGT activities were not affected by 
MMI if its thyroid hormone-lowering effect was prevented 
by T4 treatment. In addition, neither androsterone nor 
bilirubin UGT activity was influenced when MMI was 
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Table 2 
Effects of Treatment of Rats with MMI and T4 vs T4 Alone 
on Serum T4 and T3 levels and Hepatic ID-I Activity '~ 
Treatment 
Parameter T4 T4 + MMI 
T4, nmol/L 156.3 _+ 56.8 132.5_+22.5 
T3, nmol/L 1.19 + 0.20 1.27 _+ 0.34 
ID-I, pmol/min/mg 883 _+ 71 899 _+ 130 
" Rats were treated for2 wk with daily ip injections of I gg T4/ 
100 g body wt and 0.1% (wt/vol) MM] in the drinking water or 
with T4 alone. Results are presented as mean _+ SD of eight rats 
in each group. 
Table 3 
Effects of Thyroidectomy on Serum T4, T3 and TSH Levels 
and Hepatic ID-I Activity" 
Group 
Parameter Control Thyroidectomized 
T4, nmol/L 42.0 _+ 10.4 8.8 + 4.7 h 
Y3, nmol/L 0.86 + 0.32 0.45 + 0.14 < 
TSH (ng/ml) 0.82 -+ 0.57 10.46 _+ 3.92 ~' 
ID-l, pmol/min/mg 1125 + 261 559 + 164/' 
c, Results are presented as mean • SD of four control and eight 
thyroidectomized rats. 
t,p < 0.001 vs control. 
<p < 0.01 vs control. 
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Fig. 2. Et'ti~cis of treatment of rats for2 wk with daily injections of 
[ Bg ]'4/100 g body wt and 0. t% (wt/vol) MMI in the drinking 
water or with T4 alone (control) on hepatic UGT activities. Results 
are expressed as percentage of the mean control value (T4 1.94 
pmol, T3 1.36 pmol, PNP 49 nmol, bilirubin 0.96 nmol, and andros- 
terone 6.88 nmol per min and per mg protein), and presented as 
mean -+ SD of eight rats per group. *,p < 0.001 vs control. 
Subst ra te  
Fig. 3. Effects of thyroidectomy on hepatic UGT activities. 
Results are expressed as percentage of the mean control value 
(T4 2.32 pmol, T3 1.91 pmol, PNP 49 nmol, bilirubin 0.62 nmol, 
and androsterone 3.87 nmol per rain and per mg protein), and 
presented as mean + SD of four control and eight thyroid- 
ectomized rats. O ,p  < 0.05 vs control; *,p < 0.001 vs control. 
administered in combination with T4. However, PNP UGT 
activity was almost threefold higher in rats treated with 
MMI and T4 than in rats receiving only T4. 
Table 3 shows the serum hormone levels and hepatic 
ID-I activity in thyroidectomized rats and euthyroid con- 
trois. Serum T4 was decreased by about 80% and serum T3 
by about 50%, whereas erum TSH was increased,~ 13-fold 
after thyroidectomy. The hypothyroid status of  the livers o f  
the thyroidectomized animals is indicated by the ~50% 
decrease in ID-I activity. 
Figure 3 shows the effects of  thyroidectomy on hepatic 
UGT activities. T4 UGT activity was significantly higher 
in thyroidectomized than in control rats, but T3 UGT activ- 
ity was not affected by thyroidectomy. PNP UGT activity 
was significantly decreased and bilirubin UGT activity was 
significantly increased after thyroidectomy. Androsterone 
UGT activity was not affected in the thyroidectomized 
animals. 
Table 4 shows the effects o f  treatment o f  rats for 1 wk 
with daily injections of  10 lag T4/100 g body wt on serum 
T4 and T3 levels and on hepatic ID-I activity. All these 
parameters were >2-fold higher in the hyperthyroid ani- 
mals than in the euthyroid controls. 
Figure 4 presents the effects o f  hyperthyroidism on 
hepatic UGT activities for different substrates. T4 but not 
T3 UGT activity was slightly decreased in the hyperthyroid 
rats. PNP activity was ~80% increased and bilirubin UGT 
activity ,z50% decreased in hyperthyroid vs euthyroid rats. 
Androsterone UGT activity was not significantly affected 
by induction o f  hyperthyroidism. 
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Table 4 
Effects of Treatment of Rats with Excess T4 on Serum T4 
and T3 Levels and Hepatic ID-! Activity" 
Treatment 
Parameter Control T4 
T4, nmol/L 57 + 10 125 + 9 b 
T3, nmol/L 1.62 + 0.15 3.37 _+ 0.81 ~ 
ID-I, pmol/min/mg 419 + 85 1048 + 191 b 
a Rats were treated for l wk with daily ip injections of 10 gg 
T4/100 g body wt or vehicle. Results are presented as mean + SD 
of eight rats in both groups. 
bp < 0.001 vs control. 
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Fig. 4. Effects of T4-induced hyperthyroidism on hepatic UGT 
activities. Results are expressed as percentage ofthe mean control 
value (T4 1.14 pmol, T3 0.98 pmol, PNP 63 nmol, bilirubin 0.53 
nmol, and androsterone 3.57 nmol per min and per mg protein), and 
expressed as mean _+ SD of eight rats per groups. For T3 and 
androsterone UGT activities: n= 7 (one LA rat in each group). O, 
p < 0.05 vs control; Q,p < 0.025 vs control; *,p < 0.001 vs control. 
Discussion 
Previous work in our laboratory has suggested that at 
least three UGT isoenzymes are involved with the glucu- 
ronidation ofT4 and T3 in rat liver (Beetstra et al., 1991; 
Visser et al., 1991a, 1993a, 1993b; Van Raaij et al., 1993). 
This was based on the following findings: 
1. Parallel with an increase in PNP UGT activity, hepatic T4 
but not T3 UGT activity is strongly induced by treatment 
of rats with 3-methylcholanthrene (MC)-type inducers; 
2. Parallel with an increase in bilirubin UGT activity, hepatic 
T4 but not T3 UGT activity is strongly induced by treat- 
ment of rats with clofibrate or ciprofibrate; 
3. Hepatic T4 but not T3 UGT activity is strongly decreased 
in Gunn rats, which have a defect in the UGT1 gene coding 
for multiple bilirubin and phenol UGTs (Emi et al., 1995); 
4. Relative to normal Wistar HA (high activity) rats, T3 but not 
T4 UGT activity is strongly decreased in Wistar EA (low 
activity), Fischer, and WAG rats, which have a defect in the 
gene coding for androsterone UGT (Homma et al., 1992). 
These results, thus, suggest hat T4 is predorninantly 
glucuronidated in rat liver by both bilirubin UGT and phe- 
nol UGT, whereas T3 is primarily conjugated by androster- 
one UGT. This is supported by studies with V79 cell lines 
transfected with cDNA of different human UGT isoen- 
zymes, showing significant glucuronidation fT4 (and rT3) 
by the bilirubin UGT HP3, as well as the phenol UGT HP4 
(Visser et al., 1993c). However, in contrast o the latter 
"bulky" phenol-preferring isoenzyme, little or no glucu- 
ronidation ofiodothyronines was observed with the planar 
phenol-preferring isoenzyme HPI, which glucuronidates 
substrates such as 1 -naphthol and PNP. Therefore, the par- 
allel increase in iodothyronine and PNP UGT activities in 
response to MC-type inducers does not--as we initially 
suggested (Beetstra et al., 1991)--reflect the induction of 
a common enzyme but rather the simultaneous induction of 
different isoenzymes, i.e., one for PNP (HPI-like) and one 
for iodothyronines (HP4-1ike) (Visser et al., 1993b). 
Drugs and xenobiotics that accelerate the metabolic 
clearance ofT4 by induction ofUGT isoenzymes include poly- 
chlorobiphenyls, dioxin, fibrates, phenobarbital, nd other 
anticolvulsant drugs (McClain et al, 1989; Beetstra et al., 
1991; Visser et al., 1991a, 1993b; Saito et al., 1991; De 
Sandro et al., 1991,1992; Barter and Klaassen, 1992a, 1992b: 
Van Raaij et al., 1993). The resultant decrease in serum T4 
causes an increase in TSH secretion and, thus, a stimulation 
of thyroid activity. Chronic treatment with such compounds 
may even be associated with development ofthyroid tumors 
in rats (McClain, 1989) and of goiter in humans (Hegediis 
et al., 1985; Davies and Franklin, 1991 ). Although glucuroni- 
dation is also under normal conditions amajor pathway of 
thyroid hormone metabolism in rats and perhaps also in 
humans, little is known about its regulation. It has previ- 
ously been reported that bilirubin UGT activity is increased 
while PNP UGT activity is decreased in thyroidectomized 
rats (Roy Chowdhury et al., 1983; Van Steenbergen etal., 
1989). Conversely, bilirubin UGT activity is decreased 
while PNP UGT activity is increased in hyperthyroid rats 
(,Roy Chowdhury et al., 1983; Van Steenbergen t al., 1989). 
Therefore, we investigated the possible effects of thyroid 
status on hepatic UGT activities for the iodothyronines T4
and T3 in comparison with the UGT activities for the "stan- 
dard" substrates bilirubin, PNP, and androsterone. 
Initially, the effects of hypothyroidism were investigated 
in rats that had been made hypothyroid by treatment with 
PTU or MMI. In agreement with the aforementioned pub- 
lished reports (Roy Chowdhury et al., 1983; Van Steen- 
bergen et al., 1989), we found that hepatic bilirubin UGT 
activity was significantly increased in MMI- or PTU- 
induced hypothyroid rats. In contrast o the previously 
reported ecrease inPNP UGT activity in thyroidectomized 
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rats (Roy Chowdhury et al., 1983; Van Steenbergen tal., 
1989), we noticed a slight increase in PNP UGT activity in 
PTU-treated rats and a marked enzyme induction in 
MMI-treated rats. This suggested a direct induction of PNP 
UGT by MMI and to some extent also by PTU, not medi- 
ated by their thyrostatic action. This possibility was tested 
by administration ofMMI to rats in which the induction of 
hypothyroidism was prevented by replacement doses of T4. 
In this setting, MMI did not affect he thyroid status of the 
animals, since not only serum T4 and T3 levels but also 
hepatic ID-I activity was identical in rats treated with MMI 
and T4 and in those treated with T4 alone. Bilirubin UGT 
activity was not affected by administration of MMI to 
T4-substituted rats, but PNP UGT was markedly induced 
by the thyrostatic drug. This supports the direct induction 
of PNP UGT in rat liver by MMI. 
Our results in thyroidectomized rats are in agreement 
with the aforementioned reports (Roy Chowdhury et al., 
1983; Van Steenbergen tal., 1989), since we observed an 
increase in bilirubin UGT activity and a decrease in PNP 
UGT activity compared with euthyroid controls. Also in 
agreement with the literature, we found a decreased biliru- 
bin UGT activity and an increased PNP UGT activity in 
hyperthyroid animals. At least two bilirubin UGTs and at 
least two phenol UGTs are encoded by the UGTI gene, a 
gene complex comprising muItiple unique exons (exons I) 
and a set of four common exons (exons II-V) (Emi et al., 
1995). Transcription may start at any of the different unique 
exons, each under control of its own promoters, yielding 
primary transcripts of varying length depending on the 
location of the relevant exon I in the UGT1 gene. By differ- 
ential splicing of these primary transcripts, multiple mRNA 
species are produced that each combine a unique exon I, 
coding for the substrate-binding domain, with the common 
exons II-V, coding for the cofactor-binding domain of the 
enzyme (Owens and Ritter, 1992; Burchell et al., 1994; 
Emi et al., 1995). An attractive xplanation of the effects of 
thyroid status on bilirubin and PNP UGT activities is that 
the promoter of one or more bilirubin UGT-specific exons I
is under negative control of the T3 receptor, whereas the 
promoter of one or more phenol UGT-specific exons I is 
under positive control of the T3 receptor. Further studies 
are required to test this hypothesis. It also remains to be 
determined if it is the same phenol UGT isoenzyme(s) 
that is (are) regulated by thyroid hormone as well as 
induced by MMI. 
Except for two preliminary communications in abstract 
form (Visser et al., 1991 b; Van der Heide et at., 1992), the 
effects of thyroid status on hepatic iodothyronine UGT 
activity have not been reported before. Our results demon- 
strate that T4 UGT activity is significantly increased in 
hypothyroid rats and marginally decreased inhyperthyroid 
animals. It is tempting to explain these effects by the par- 
allel variations in bilirubin UGT activity, for which T4 is 
known to be a substrate (Visser et al., 1993c). Both T3 and 
androsterone UGT activities were significantly increased 
by MMI or PTU treatment but unaffected by thyroidectomy. 
These different responses may be explained by the more 
severe hypothyroidism induced by the drugs than by 
thyroidectomy, which is supported by the larger decrease 
in hepatic ID-I activity in MMl-treated than in thyroidec- 
tomized rats. The larger increase in T3 than in androsterone 
UGT activity in drug-induced hypothyroidism suggests hat 
T3 is also glucuronidated to some extent by bilirubin UGT. 
The relevance of the observed changes in iodothyronine 
UGT activities for the thyroid status-dependent regulation 
of thyroid hormone metabolism remains to be determined. 
It should be realized that in vivo changes in cofactor 
(UDPGA) concentrations may be as important as changes 
in UGT activity in determining overall hepatic glucuroni- 
dation (Qu et al., 1995), and the effects of thyroid status on 
hepatic UDPGA levels are unknown. The opposite changes 
in ID-I and T4 UGT activities suggest hat hepatic T4 
metabolism shifts from deiodination to glucuronidation i  
hypothyroid rats and vice versa in hyperthyroid animals. 
The importance of glucuronidation for thyroid hormone 
metabolism in humans has not been established. Glucu- 
ronidation ofT4 has been demonstrated with human liver 
microsomes and human bilirubin and phenol UGTs (Visser 
et al., 1993c). These enzymes are encoded by a similar 
UGT1 gene complex as in rats (Owens and Ritter, 1992; 
Burchell et al., 1994; Emi et al., 1995), but it is unknown if 
their expression is also regulated by thyroid hormone. 
In conclusion, we have demonstrated that iodothyronine 
UGT activity in rat liver is markedly increased in hypo- 
thyroidism and slightly decreased inhyperthyroidism, prob- 
ably reflecting the parallel changes in bilirubin UGT activity. 
PNP UGT activity is strongly induced by MMI treatment, 
which is independent ofthe thyrostatic potency of this drug. 
Materials and Methods 
Materials 
[3',5'-12SI]T4, [3'-1251]T3, and [3',5'-t2Sl]rT3 were 
obtained from Amersham (Amersham, England); T4, T3, 
PTU, MMI, dithiothreitol (DTT), bilirubin, and BSA from 
Sigma (St. Louis, MO); rT3 from Henning (Berlin, Ger- 
many); [3H]androsterone from NEN (Boston, MA); andros- 
terone from Steraloids (Wilton, Nit); PNP from Merck 
(Darmstadt, Germany); Brij 56 and Brij 58 from Serva 
(Heidelberg, Germany); UDP-glucuronic acid (UDPGA) 
from Boehringer Mannheim (Almere, The Netherlands); 
BCA protein assay reagent from Pierce (Oud Beijerland, 
The Netherlands); and Sephadex LH-20 from Pharmacia 
(Woerden, The Netherlands). 
The purity of[ 125I]T3 was checked by chromatography 
on Sephadex LH-20, showing that it could be used without 
further purification. [125I]T4 and [i 25i]rT 3 were purified on 
Sephadex LH-20 immediately before each assay (Visser 
et al., 1993b) 
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Rat Treatments 
All experiments were done with groups of eight male 
Wistar rats (weighing 20C~350 g) obtained from Harlan 
Sprague-Dawley (Zeist, The Netherlands) or bred locally. 
They were housed in a controlled animal room with a 14-h 
light: 10-h dark photocycle, and they were provided ad libi- 
turn with food and drinking water. Rats were made hypothy- 
roid by treatment for 2 wk with drinking water containing 
0.1% (wt/vol) PTU or MMI. Euthyroid controls received 
plain drinking water. To check for nonthyrostatic effects of 
MMI, rats were treated for 2 wk with 0.1% MMI in the 
drinking water and daily ip injections with 1 ~tg T4/100 g 
body wt, whereas controls received the same T4 injections 
but no MMI. Rats were also made hypothyroid by surgical 
thyroidectomy under ether anesthesia followed after 1 wk 
by administration of 0.75 mCi131I : they were sacrificed 
two weeks later. Hyperthroidism was induced by treating 
rats for 7 d with daily ip injections of 10 lag T4/100 g body 
wt, whereas control rats received injections with vehicle. 
At the end of the treatments (24 h after the last T4 dose), 
rats were anesthetized with ether and decapitated. Trunk 
blood was collected and serum was isolated and stored at 
20~ until analysis of hormone levels. Livers were iso- 
late& immediately frozen in liquid nitrogen, and stored at 
80~ until further processing. All procedures were 
approved by the Animal Welfare Committee (DEC) of the 
Erasmus University. 
Liver Enzyme Assays 
Liver microsomes were prepared as previously described 
(Visser et al., 1993b), suspended in0.1Mphosphate (pH 7.2), 
2 mM EDTA and 1 mM DTT, at a protein concentration of
10-20 mg/mL, and stored in aliquots at-80~ until enzyme 
analysis. Protein was measured with the BCA reagent 
according to the protocol of the supplier, using BSA as 
the standard. 
Iodothyronine UGT activities were assayed usually by 
incubation of 1 ~tM T4 or T3 and 100,000 cpm of the 
~ 25I-labeled compound for 60 rain at 37~ with microsomes 
(1 mg protein/rnL) and 5 mM UDPGA in 0.2 mL 75 mM 
Yris/HC1 (pH 7.8) and 7.5 mM MgC12 in the presence of 
0.025% (wt/vol) Brij 56 (Visser et al., 1993b). The reac- 
tions were stopped by addition of 0.2 mL ice-cold metha- 
nol, and after centrifugation, 200 btL of the supernatants 
were mixed with 0.8 mL 0.1M HC1 and analyzed for glucu- 
ronide formation by chromatography on small Sephadex 
LH-20 columns (Visser et al., 1993b), 
UGT activities for PNP, bilirubin, and androsterone were 
measured as previously described (Visser et al., 1993b). In 
short, assay mixtures for PNP UGT activity contained final 
concentrations of I mM PNP, 5 mM UDPGA, 0.25 mg 
microsomal protein/mL, 0.005% Brij 58, 0.1M Tris/HCl 
(pH 7.4), and 5 mM MgC12, and were incubated for 5-  
15 rain at 37~ Assay mixtures for bilirubin UGT activity 
contained 0.1 mMbilirubin, 0.125% BSA, 5 mMUDPGA, 
1 mg microsomal protein/mL, 0,025% Brij 56, 0. I M Tris/ 
HC1 (pH 7,8), and 3.75 lnM MgC1 e, and were incubated for 
I5 min at 37~ Androsterone UGT assay mixtures con- 
tained 0.1 mM androsterone, ~50,000 dpm [3H]andros- 
terone, 5 mM UDPGA, 0.5 mg microsomal protein/mL, 
0.005% Brij 56, 0.1 mM Tris/HCl (pH 7.4) and 3.75 mM 
MgCI2, and were incubated for 15 rain at 37~ 
Type I iodothyronine deiodinase (ID-I) activity was 
determined essentially as previously described by incuba- 
tion of I  gMrT3 and ~1 00,000 cpm [125I]rT3 for 30 rain 
at 37~ with 10 gg microsomal protein/mL in 0.1Mphos- 
phate (pH 7.2), 2 mM EDTA, and 5 mM DTT (Visser 
et al., 1993b). 
Miscellaneous 
Serum T4 and T3 levels were determined by standard 
RIA procedures. Serum TSH was determined by RIA with 
the materials and protocols of the NIDDK, using TSH RP-2 
as standard. Data are presented as mean _+ SD. The statis- 
tical significance of differences between groups of con- 
trol and experimental nimals was evaluated with Student's 
t-test. P < 0.05 was considered significant 
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